Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


13.06.2022

1 BMC Cancer
1 Cancer
1 Cancer Res
1 Clin Cancer Res
1 Discov Oncol
3 Eur Urol
1 Int J Cancer
4 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
1 J Nucl Med
1 Lancet Oncol
2 Nat Rev Urol
1 Oncogene
1 Oncol Rep
1 PLoS Med
1 PLoS One
9 Prostate
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Cancer

  1. ABERA SF, Bedir A, Glowka A, Vordermark D, et al
    Suboptimal use of hormonal therapy among German men with localized high-risk prostate Cancer during 2005 to 2015: analysis of registry data.
    BMC Cancer. 2022;22:624.
    PubMed         Abstract available


    Cancer

  2. O'ROURKE K
    Can multiparametric ultrasound be used for prostate cancer?
    Cancer. 2022;128:2399.
    PubMed        


    Cancer Res

  3. PATEL R, Ford CA, Rodgers L, Rushworth LK, et al
    Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression.
    Cancer Res. 2022 Jun 8. pii: 704813. doi: 10.1158/0008-5472.CAN-21-1301.
    PubMed         Abstract available


    Clin Cancer Res

  4. CHAKRABORTY G, Nandakumar S, Hirani R, Nguyen B, et al
    The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer.
    Clin Cancer Res. 2022 Jun 7. pii: 699404. doi: 10.1158/1078-0432.CCR-21-4272.
    PubMed         Abstract available


    Discov Oncol

  5. HNIT SST, Yao M, Xie C, Bi L, et al
    Apigenin impedes cell cycle progression at G2 phase in prostate cancer cells.
    Discov Oncol. 2022;13:44.
    PubMed         Abstract available


    Eur Urol

  6. ROCCO B, Sighinolfi MC, Coelho RF, Covas Moschovas M, et al
    Re: Trends in Incidence of Metastatic Prostate Cancer in the US.
    Eur Urol. 2022 Jun 2. pii: S0302-2838(22)02271.
    PubMed        

  7. MONTORSI F, Stabile A, Mazzone E, Gandaglia G, et al
    Re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol 2022;81:407-13
    Eur Urol. 2022 Jun 2. pii: S0302-2838(22)02394.
    PubMed        

  8. BURNS D, Anokian E, Saunders EJ, Bristow RG, et al
    Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.
    Eur Urol. 2022 May 31. pii: S0302-2838(22)02341.
    PubMed         Abstract available


    Int J Cancer

  9. JAMES ND, Clarke NW, Cook A, Ali A, et al
    Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
    Int J Cancer. 2022;151:422-434.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  10. HALL WA, Karrison TG, Rosenthal SA, Amin MB, et al
    The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High Risk Prostate Cancer: A Validation Study from NRG/RTOG 0521.
    Int J Radiat Oncol Biol Phys. 2022 Jun 5. pii: S0360-3016(22)00555.
    PubMed         Abstract available

  11. RICH BJ, Montoya C, Jin WH, Spieler BO, et al
    Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jun 4. pii: S0360-3016(22)00545.
    PubMed         Abstract available

  12. LUCIEN F, Kim Y, Qian J, Orme JJ, et al
    Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity.
    Int J Radiat Oncol Biol Phys. 2022 Jun 4. pii: S0360-3016(22)00544.
    PubMed         Abstract available

  13. ZAMBOGLOU C, Strouthos I, Sahlmann J, Farolfi A, et al
    Metastasis-free survival and patterns of distant metastatic disease after PSMA-PET-guided salvage radiotherapy in recurrent or persistent prostate cancer after prostatectomy.
    Int J Radiat Oncol Biol Phys. 2022 Jun 2. pii: S0360-3016(22)00409.
    PubMed         Abstract available


    J Clin Oncol

  14. MADAN RA, Mena E, Lindenberg L, Choyke PL, et al
    With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer.
    J Clin Oncol. 2022 Jun 3:JCO2200493. doi: 10.1200/JCO.22.00493.
    PubMed        


    J Nucl Med

  15. JADVAR H
    The VISION Forward: Recognition and Implication of PSMA-/(18)F-FDG+ mCRPC.
    J Nucl Med. 2022;63:812-815.
    PubMed         Abstract available


    Lancet Oncol

  16. BRAY F, Parkin DM
    Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs.
    Lancet Oncol. 2022;23:719-728.
    PubMed         Abstract available


    Nat Rev Urol

  17. EBNER B, Volz Y, Mumm JN, Stief CG, et al
    The COVID-19 pandemic - what have urologists learned?
    Nat Rev Urol. 2022;19:344-356.
    PubMed         Abstract available

  18. SEYFRIED TN
    The effects of diet on prostate cancer outcomes.
    Nat Rev Urol. 2022 Jun 8. pii: 10.1038/s41585-022-00612.
    PubMed        


    Oncogene

  19. SUN F, Wang X, Hu J, Liu J, et al
    RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway.
    Oncogene. 2022;41:3239-3250.
    PubMed         Abstract available


    Oncol Rep

  20. LIN J, Chen Z, Li Z, Nong D, et al
    [Corrigendum] Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer.
    Oncol Rep. 2022;48.
    PubMed         Abstract available


    PLoS Med

  21. PARKER CC, James ND, Brawley CD, Clarke NW, et al
    Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
    PLoS Med. 2022;19:e1003998.
    PubMed         Abstract available


    PLoS One

  22. MOKOATLE M, Mapiye D, Marivate V, Hayes VM, et al
    Discriminatory Gleason grade group signatures of prostate cancer: An application of machine learning methods.
    PLoS One. 2022;17:e0267714.
    PubMed         Abstract available


    Prostate

  23. STENZL A, Szmulewitz RZ, Petrylak D, Holzbeierlein J, et al
    The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
    Prostate. 2022 Jun 8. doi: 10.1002/pros.24396.
    PubMed         Abstract available

  24. KWAN EM, Wyatt AW
    Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer.
    Prostate. 2022;82 Suppl 1:S25-S36.
    PubMed         Abstract available

  25. SUTERA P, Deek MP, Van der Eecken K, Wyatt AW, et al
    Genomic biomarkers to guide precision radiotherapy in prostate cancer.
    Prostate. 2022;82 Suppl 1:S73-S85.
    PubMed         Abstract available

  26. KHAN HM, Cheng HH
    Germline genetics of prostate cancer.
    Prostate. 2022;82 Suppl 1:S3-S12.
    PubMed         Abstract available

  27. CRESTA MORGADO P, Mateo J
    Clinical implications of homologous recombination repair mutations in prostate cancer.
    Prostate. 2022;82 Suppl 1:S45-S59.
    PubMed         Abstract available

  28. COTTER K, Rubin MA
    The evolving landscape of prostate cancer somatic mutations.
    Prostate. 2022;82 Suppl 1:S13-S24.
    PubMed         Abstract available

  29. ANTONARAKIS ES
    Genetics and genomics of prostate cancer and therapeutic implications.
    Prostate. 2022;82 Suppl 1:S1-S2.
    PubMed        

  30. MIZUNO K, Beltran H
    Future directions for precision oncology in prostate cancer.
    Prostate. 2022;82 Suppl 1:S86-S96.
    PubMed         Abstract available

  31. CHOUDHURY AD
    PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
    Prostate. 2022;82 Suppl 1:S60-S72.
    PubMed         Abstract available


    Urology

  32. BENIDIR T, Hofmann M, Lone Z, Nguyen JK, et al
    Elevated IsoPSA Selects for Clinically Significant Prostate Cancer Without a Preference for Any Particular Adverse Histopathologic or Radiographic Feature.
    Urology. 2022 Jun 6. pii: S0090-4295(22)00449.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: